Point-of-care rapid RNA test for zika crosslife technologies INC
Ended Project Grant Awarded Last action
- Award ID
- R44TR003549
- Recipient
-
Crosslife Technologies Inc. UEI LFE6DJ6KL4E5
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,999,748
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date
- Funding
-
- $1,999,832.00 Federal
- $999,916.00 Non-federal
- Place of performance
- Carlsbad, CA 92008, USA
Award details come from USAspending.gov.
Description
Project summary/abstract we aim to develop a rapid point-of-test that detects zikv at the point-of-need in < 30 minutes and is appropriate for non-laboratory settings and non-technical personnel. Our proprietary test exploits a novel probe reaction chemistry that allows multiplexed detection of DNA or RNA without sample purification, making IT operable as a simple, hand-held test. Patient samples to be input directly into the device without pre- processing and a disposable cartridge carry out amplification of all targets and reports visible results that can be read by eye. We have demonstrated the feasibility of a novel and simple detection of zikv using tara (templated assisted rapid assay). The key goals of the phase 2 project are to 1) develop and evaluate automated paper strip device and to 2) validate IT using clinical samples. We will evaluate the automated paper strip device using 200 samples from a navy-IRB approved protocol through our crada collaboration with U.S. Naval medical research center and the U.S. Naval medical research unit six. We expect a sensitivity (>90%) and specificity (>90%) to the QRT-PCR data on the same samples. The successful achievement of 1) time to result < 30 min, 2) sensitivity > 90%, specificity > 90% and LOD < 500 copies/test, 3) > 90% user feedback on ease of use need for clia waiver, 4) requires no instrumentation, power source, or refrigeration of reagents, and 5) quantitative criteria for measuring the outcome of each task are exceeds or equivalent to the RT-PCR molecular test.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $999,916 | $0 | |
| Original award | $999,916 | $999,916 |
Quick answers
Who received award R44TR003549?
R44TR003549 was awarded to Crosslife Technologies Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on January 15, 2021.
How much is award R44TR003549 worth?
$2,999,748 has been obligated on R44TR003549: $1,999,832 in federal funding and $999,916 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award